Existing biomarkers, such as programmed cell death‐ligand 1 (PD‐L1), mismatch repair (MMR) deficiency, and tumor mutational burden (TMB), were reported to have limited precision to predict clinical outcomes of patients treated with ICIs.4, 5. The gene discussed is CD274; the disease is neoplasm.